Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Vividion Therapeutics
Vividion is a biotechnology company that develops drug discovery platform.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Mersana Therapeutics
Mersana Therapeutics develops a biodegradable polymer platform to create new and better medicines.
Sector
Subsector
Keywords
Location
total rounds
total raised
Finch Therapeutics
Finch Therapeutics is a microbiome engineering company that develops microbial therapies for patients with unmet medical needs.
Sector
Subsector
Keywords
Location
total rounds
total raised
Arrakis Therapeutics
Arrakis Therapeutics develops drugs to treat neurological disorders and other diseases using a drug discovery platform that targets RNA.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 15.11.2022. Their latest investor Pfizer Venture Investments. Their latest round Series C
Bain Capital Life Sciences
Bain Capital Life Sciences Fund focuses on buyouts, growth capital, and private equity investments in the life sciences sector.
Sector
Subsector
Location
count Of Investments
count Of Exists
RA Capital Management
RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Polaris Partners
Polaris Partners is a venture capital firm that invests in healthcare and technology companies at all stages of growth.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Pfizer Venture Investments
Pfizer Venture Investments is a VC firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
RA Capital Management
RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Matthew Hammond
Matthew Hammond is a Principal at RA Capital Management. Matthew Hammond attended The University of Connecticut Health Center.
current job
Bain Capital Life Sciences
Bain Capital Life Sciences Fund focuses on buyouts, growth capital, and private equity investments in the life sciences sector.
Sector
Subsector
Location
count Of Investments
count Of Exists
Ronald Renaud
Ronald Renaud has served as the President and chief executive officer of Idenix Pharmaceuticals, Inc. since October 2010. Prior to this, Ronald Renaud has served as the chief financial officer of Idenix Pharmaceuticals, Inc. since June 2007 and additionally as Chief Business Officer since June 2010. Ronald Renaud brings a unique mix of skills to this role with his finance experience at public biotechnology companies and on Wall Street, as well as his science background. Prior to joining Idenix, Ronald Renaud served as chief financial officer of Keryx Biopharmaceuticals. In this role he was responsible for the strategic planning and development of the finance function to support the company’s growth and its late-stage product candidate development. Prior to his position at Keryx, he spent several years as a senior biotechnology equity analyst for leading investment banks including Bear Stearns, Schwab SoundView and JP Morgan. Additional industry experience includes Mr. Renaud's more than five years at Amgen Inc., where he held positions in clinical research, investor relations and finance. Ronald Renaud holds a Masters in Business Administration from the Marshall School of Business at the University of Southern California and a Bachelor of Arts from St. Anselm College in Manchester, NH.
current job
People
Founders5
Amir Nashat
Amir Nashat is a Managing Partner in Polaris’ Boston office. Amir joined Polaris in 2002 and focuses on investments in healthcare. Amir currently represents Polaris as a Member of the Board of Directors at AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), BIND Therapeutics (NASDAQ: BIND), Fate Therapeutics (NASDAQ: FATE), Metacrine, Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences, and Syros Pharmaceuticals. Additionally, Amir has served as a Member of the Board of Directors at Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Living Proof, Pervasis Therapeutics (Shire Pharmaceuticals), Receptos (Celgene) and Sun Catalytix (Lockheed Martin). At Living Proof and Sun Catalytix, Amir served as the company’s initial Chief Executive Officer. Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. Amir previously served on the Board of the New England Venture Capital Association. Amir has been named to the Forbes Midas List of “Top 100 Venture Capitalists.” Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his M.S. degree and B.S. degree in Materials Science and Mechanical Engineering at the University of California, Berkeley.
current job
Amir Nashat
Stuart L. Schreiber
Stuart Schreiber's lab studies the science of therapeutics. Researchers in his group rely on human biology to identify therapeutic targets that have been validated prior to testing in humans, and chemistry and chemical biology to discover small molecules that modulate the targets in ways required to provide relief or protection from disease. Schreiber and his group members have discovered principles that underlie information transfer and storage in cells, specifically discoveries relating to signaling by the phosphatase calcineurin and kinase mTOR (demonstrating for the first time that drugs can result from the targeting of protein kinases and protein phosphatases), gene regulation by chromatin-modifying histone deacetylases, small-molecule dimerizers that activate cellular processes by enforced proximity, and small-molecule probes of challenging targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation) that relate to human disease. Their work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in an open data-sharing environment.
current job
organization founded
Stuart L. Schreiber
Joel Barrish
Joel came to Jnana from Achillion Pharmaceuticals, where he served as CSO. Most of Joel’s career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last 5 years as Vice President and Head of Discovery Chemistry, working across all therapeutic areas. During his BMS career, Joel worked with teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. He is a co-author on over 130 peer reviewed publications and is a co-inventor on 40 issued U.S. patents. Joel received a Ph.D. in Organic Chemistry from Columbia University working with Professor W. Clark Still. He spent 5 years at Hoffmann La-Roche prior to moving to BMS.
current job
organization founded
Joel Barrish
Employee Profiles11
John Throup
Senior Vice President, Head of Development
Heather Smith Blanchette
VP Nonclinical Development
